Method of optimizing the treatment of Philadelphia-positive leukemia with Abl tyrosine kinase inhibitors

Details for Australian Patent Application No. 2007299764 (hide)

Owner Novartis AG

Inventors Gathmann, Insa; Picard, Stephane; Mahon, Francois-Xavier; Molimard, Mathieu; Wang, Yanfeng

Agent Davies Collison Cave

Pub. Number AU-B-2007299764

PCT Pub. Number WO2008/036792

Priority 60/826,622 22.09.06 US; 60/828,278 05.10.06 US

Filing date 20 September 2007

Wipo publication date 27 March 2008

Acceptance publication date 13 October 2011

International Classifications

A61K 49/00 (2006.01) Preparations for testing

A61K 31/00 (2006.01)

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 35/02 (2006.01) Antineoplastic agents

Event Publications

2 April 2009 PCT application entered the National Phase

  PCT publication WO2008/036792 Priority application(s): WO2008/036792

13 October 2011 Application Accepted

  Published as AU-B-2007299764

2 February 2012 Opposition Lodged

  Peachey, B. has lodged an opposition against Novartis AG.

11 October 2012 Opposition Withdrawn

  The opposition by Peachey, B. against Novartis AG has been withdrawn.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007299774-Antibody-based arrays for detecting multiple signal transducers in rare circulating cells

2007299748-miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention